Drug sensitivity markers for your compound can be investigated using the response parameters of cancer cell line profiling, without the need for additional experiments. For instance, we perform analysis on IC50values and gene mutation data to identify genomic drug response biomarkers for cancer. Case studies have confirmed patient stratification markers that have been used in the clinic (Uitdehaag et al., 2019).
Oncolines™ bioinformatics analysis can be done for IC50 values or other response parameters, for instance GI50 or Area Under the Curve (AUC). The analysis is available for proliferation data from the Oncolines™ cancer cell line panel as well as proliferation data that have been generated elsewhere.
The analysis indicates whether anti cancer drugs or drug candidates show preferential activity in a certain cancer tissue type.
Drug sensitivity data is coupled to gene expression data. It uses large datasets of gene expression to identify interconnections between sensitivity and resistance to your anti cancer drug and gene transcription (Uitdehaag et al., 2019).
We can use your internal cancer cell line proliferation data or Oncolines™ proliferation results